Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.61 0.87 (0.99%) as of 4:30 Wed 3/27


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.69(B)
Last Volume: 1,031,697 Avg Vol: 1,398,626
52 Week Range: $76.22 - $100.3
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:

    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 92,341 116,105 269,465 610,463
Total Sell Value $8,237,699 $10,489,308 $24,880,826 $57,517,351
Total People Sold 3 4 5 8
Total Sell Transactions 9 11 22 59
End Date 2023-12-28 2023-09-26 2023-03-28 2022-03-28

   
Records found: 1356
  Page 6 of 55  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-05-15 4 D $57.44 $283,294 D/D (4,932) 180,257     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-05-15 4 D $57.44 $116,948 D/D (2,036) 62,814     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-05-15 4 D $57.44 $62,954 D/D (1,096) 21,984     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-05-15 4 D $57.44 $71,283 D/D (1,241) 63,126     -
   Mueller Brian VP, Corporate Controller   •       –      –    2014-05-15 4 D $57.44 $11,890 D/D (207) 8,290     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-05-13 4/A S $58.23 $83,498 D/D (1,434) 63,415     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-05-13 4 S $58.23 $83,498 D/D (1,434) 64,850     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-05-13 4 AS $58.18 $27,809 D/D (478) 23,080     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-05-12 4/A D $59.30 $177,959 D/D (3,001) 64,849     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-05-12 4 D $57.44 $62,954 D/D (1,096) 56,768     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-05-12 4 D $59.30 $64,993 D/D (1,096) 57,864     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-05-12 4 D $59.30 $270,823 D/D (4,567) 185,189     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-05-12 4 D $59.30 $92,864 D/D (1,566) 66,284     -
   Mueller Brian VP, Corporate Controller   •       –      –    2014-05-12 4 D $59.30 $16,723 D/D (282) 8,497     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-05-12 4 D $59.30 $30,955 D/D (522) 23,558     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-05-09 4 AS $57.96 $35,992 D/D (621) 24,080     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-05-09 4 S $57.91 $201,474 D/D (3,479) 67,850     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-05-08 4 D $56.78 $96,299 D/D (1,696) 58,960     -
   Mueller Brian VP, Corporate Controller   •       –      –    2014-05-08 4 D $56.78 $25,210 D/D (444) 8,281     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-05-08 4 D $56.78 $311,098 D/D (5,479) 189,756     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-05-08 4 D $56.78 $38,554 D/D (679) 24,701     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-05-08 4 D $56.78 $143,142 D/D (2,521) 71,329     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-05-02 4 S $58.02 $644 D/D (11) 68,737     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-05-01 4 AS $59.55 $39,661 D/D (666) 25,380     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-05-01 4 S $59.67 $42,666 D/D (715) 73,850     -

  1356 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 6 of 55
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed